• closedAccess   Iron deficiency and short-term adverse events in patients with decompensated heart failure 

      Palau, Patricia; Llàcer, Pau; Domínguez Mafé, Eloy; Tormo, Juan Pablo; Zakarne, Rim; Mollar, Anna; Martínez, Ana; Miñana, Gema; Santas, Enrique; Almenar-Bonet, Luis; Fácila, Lorenzo; De la Espriella, Rafael; Núñez, Eduardo; Manzano, Luis; Bayes-Genis, Antoni; Núñez, Julio Springer (2021-03-15)
      Background: For patients with heart failure (HF), iron deficiency (ID) is a common therapeutic target. However, little is known about the utility of transferrin saturation (TSAT) or serum ferritin for risk stratification ...
    • openAccess   Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial 

      Núñez, Julio; Miñana, Gema; Cardells, Ingrid; Palau, Patricia; Llàcer, Pau; Facila Rubio, Lorenzo; Almenar-Bonet, Luis; Lopez-Lereu, Maria Pilar; Monmeneu Menadas, Jose Vicente; Amiguet Comins, Martina; González, Jessika; Serrano, Alicia; Montagud, Vicente; López‐Vilella, Raquel; Valero, Ernesto; García-Blas, Sergio; Bodí, Vicent; De la Espriella, Rafael; Lupón, Josep; Navarro, Jorge; Górriz, José Luis; Sanchis, Juan American Heart Association (2020-02-13)
      Background Intravenous ferric carboxymaltose (FCM) improves symptoms, functional capacity, and quality of life in heart failure and iron deficiency. The mechanisms underlying these effects are not fully understood. The ...